Bitcoin Updates: U.S. Postpones Bitcoin Reserve While Countries Race to Secure Digital Gold
- U.S. delays strategic Bitcoin reserve as Mike Alfred warns global competitors like Pakistan and El Salvador accelerate digital asset adoption. - Analysts highlight risks of delayed accumulation, including higher costs and reduced geopolitical influence amid early adopters securing Bitcoin at lower prices. - While Trump's executive order laid groundwork, federal inaction contrasts with global initiatives like Marshall Islands' blockchain-based UBI and Czech Republic's $1M crypto test portfolio. - Experts
According to crypto entrepreneur Mike Alfred, the U.S. government is not expected to launch its Strategic
Alfred, who often comments on Bitcoin’s role in the global economy, believes that the U.S. will only move forward under mounting international pressure. “The government will only pick up the pace when there’s enough pressure from abroad,” he said during a recent podcast,
The U.S.’s reluctance
Despite the current pause, Bitcoin’s emergence as a strategic reserve asset seems unavoidable. Alfred forecasts that Bitcoin could hit $1 million by 2033, a projection
Elsewhere, other countries are moving quickly to adopt digital assets. The Marshall Islands has introduced a Universal Basic Income (UBI) program based on blockchain technology using its USDM1 stablecoin, while El Salvador continues to strengthen Bitcoin’s status as legal currency. These developments
The U.S. is not entirely absent from these advancements.
As the pace of global adoption quickens, the U.S. stands at a pivotal point. While Alfred recognizes the progress made—citing Trump’s executive order as a significant milestone—he stresses that “progress alone isn’t sufficient” if Washington delays too long
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Updates: ETF Withdrawals and Rising Short Positions Push Bitcoin Below Bearish Threshold
- Bitcoin fell below the 0.75 cost basis quantile, a key bear-market threshold identified by Glassnode, signaling renewed downward pressure. - ETF outflows surged $866.7M on November 13, with BlackRock's IBIT and Grayscale's Bitcoin Mini Trust leading redemptions amid $100,000 price drop. - Harvard's $443M IBIT investment contrasts with bearish technical signals like the "death cross," while Nansen tracks $5.7M in new short positions. - Tight futures liquidity and 46% Fed rate-cut probability amplify downs
Bitcoin Updates Today: Is Crypto's Death Cross Indicating a Recovery or Warning of a Downturn?
- Cryptocurrency markets face selloff as Bitcoin , Ethereum , and XRP decline amid a "death cross" signal and waning institutional demand. - Technical analysis highlights Bitcoin's 50-day moving average nearing the 200-day line, historically linked to prolonged downturns or potential rebounds. - Blockchain data reveals $953M BTC moved from Mt. Gox wallets, triggering $1B in forced liquidations despite analysts labeling the transfers administrative. - Historical death crosses have preceded market bottoms, b

Aster News Today: DeFi Competition Heats Up: Incentivizing Liquidations to Draw in Traders
- Aster, a decentralized crypto exchange, launched "Machi mode" to reward traders with points for liquidations, embracing risk-taking culture. - Competitor Hyperliquid slashed taker fees by 90% via HIP-3 "growth mode," targeting liquidity providers and challenging centralized exchanges. - Both strategies reflect DeFi's arms race to attract traders through gamification (Aster) and technical efficiency (Hyperliquid), blurring financial utility with community identity. - Traders praised Aster's "failure-as-fe

Olema’s Proposal Dampens Hopes for Trial, Sparks Decline Due to Dilution Concerns
- Olema Pharmaceuticals (OLMA) shares fell 6.9-7.2% post-announcement of a stock and warrant offering, triggering dilution concerns among investors. - The TD Cowen-led offering includes a 30-day greenshoe option for up to 15% additional shares, with proceeds intended to fund breast cancer therapies like palazestrant (Phase 3) and OP-3136 (Phase 1). - Despite recent 81% stock gains and positive SERD trial data from Roche, the offering overshadowed optimism, though analysts at H.C. Wainwright and Guggenheim
